{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:42:56Z","timestamp":1768002176811,"version":"3.49.0"},"reference-count":72,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2002,5,14]],"date-time":"2002-05-14T00:00:00Z","timestamp":1021334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Liposomal daunorubicin is an effective cytotoxic agent in patients with Kaposi sarcoma and hematologic malignancies. Anthracycline\u2010based chemotherapy regimens, such as vincristine\/doxorubicin\/dexamethasone (VAD), are standard in the treatment of patients with multiple myeloma (MM). Cardiotoxicity remains a limiting factor in dose escalation of anthracyclines, and multidrug resistance (MDR) develops rapidly on exposure to anthracyclines. Liposomal daunorubicin was designed in an attempt to overcome MDR and to reduce anthracycline\u2010related toxicities. Thus, an open\u2010label, Phase II clinical study was conducted by the International Oncology Study Group to assess the efficacy and safety of intravenous liposomal daunorubicin at a dose of 100 mg\/m<jats:sup>2<\/jats:sup> given every 3 weeks for a maximum of 6 cycles in patients with recently diagnosed MM (<jats:italic>n<\/jats:italic> = 4 patients) or recurrent\/refractory MM (<jats:italic>n<\/jats:italic> = 37 patients).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Liposomal daunorubicin was administered as a single agent for the initial two cycles of therapy, and dexamethasone was added to all subsequent cycles. The primary study end point was response rates. Thirty\u2010eight patients were treated, 35 of whom were evaluable for response.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>A partial response was achieved in six patients (17%), including one patient with disease that previously was refractory to VAD therapy. Stable disease was observed in 22 patients (63%). The principal toxicity was myelosuppression. Grade 3 or 4 hematologic toxicities included granulocytopenia (26%), anemia (Grade 3 only; 11%), thrombocytopenia (11%), and febrile neutropenia (13%). The median survival in 35 patients with recurrent disease was 7.6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Liposomal daunorubicin had activity in this population of poor\u2010risk patients that was comparable to the activity of standard regimens. Further studies of this agent in combination with other anti\u2010MM agents are warranted. Cancer 2002;94:2645\u201352. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10561<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10561","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T19:28:18Z","timestamp":1030303698000},"page":"2645-2652","source":"Crossref","is-referenced-by-count":13,"title":["Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma"],"prefix":"10.1002","volume":"94","author":[{"given":"Ann F.","family":"Mohrbacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie A.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don A.","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason M.","family":"Rusk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,5,14]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(92)90527-9"},{"key":"e_1_2_5_3_2","first-page":"278","article-title":"Multiple myeloma and other differentiated B\u2010cell disorders","volume":"1","author":"Giles FJ","year":"1994","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"e_1_2_5_4_2","first-page":"88","article-title":"Current therapy of refractory multiple myeloma","volume":"13","author":"Giles FJ","year":"1995","journal-title":"Stem Cells (Dayton)"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61101-X"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701182"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.1.55"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-199907000-00004"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.12.4008"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4278.bloodjournal84124278"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.512.512"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199402173300709"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198405243102104"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900050308"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.65"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb07538.x"},{"key":"e_1_2_5_17_2","first-page":"477","article-title":"[Treatment of multiple myeloma resistant to alkylating agents with dexamethasone, vincristine and Adriamycin in continuous infusion]","volume":"54","author":"Monconduit M","year":"1987","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb08901.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb06269.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509056859"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830330203"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1852.x"},{"issue":"5","key":"e_1_2_5_23_2","first-page":"S22","article-title":"Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma","volume":"11","author":"Glasmacher A","year":"1997","journal-title":"Leukemia"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1988.243"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1200\/JCO.1994.12.12.2706","article-title":"VAD\u2010PECC regimen in the treatment of advanced\u2010stage multiple myeloma","volume":"12","author":"Delain M","year":"1994","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1715.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199512000-00003"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309148559"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(200003)63:3<125::AID-AJH3>3.0.CO;2-S"},{"key":"e_1_2_5_30_2","first-page":"121","article-title":"Refractory multiple myeloma: recent advances in therapy","volume":"9","author":"Giles FJ","year":"1995","journal-title":"Hematol Pathol"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-81-4-475"},{"key":"e_1_2_5_32_2","first-page":"23","article-title":"The cardiotoxicity of anticancer agents","volume":"9","author":"Von Hoff DD","year":"1982","journal-title":"Semin Oncol"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(89)90087-2"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200X.1997.tb03579.x"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0094-0143(05)70103-8"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.58.070189.001033"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1584"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059671"},{"key":"e_1_2_5_39_2","first-page":"182","article-title":"Drug resistance in multiple myeloma","volume":"47","author":"Sonneveld P","year":"1999","journal-title":"Pathol Biol (Paris)"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00874439"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-4811-9_55"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01505.x"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1069(199806)16:2<47::AID-HON622>3.0.CO;2-3"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199911000-00008"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050956"},{"key":"e_1_2_5_46_2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1096\/fasebj.7.6.8097173","article-title":"Modulation of doxorubicin resistance in multidrug\u2010resistant cells by liposomes","volume":"7","author":"Thierry AR","year":"1993","journal-title":"FASEB J"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0936-6555(05)80088-3"},{"key":"e_1_2_5_48_2","first-page":"2066","article-title":"Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue","volume":"56","author":"Forssen EA","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.996"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2353"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005879219554"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10156-3"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006216001681"},{"key":"e_1_2_5_54_2","first-page":"324","article-title":"Liposome encapsulated daunorubicin (daunoxome) for acute leukemia","volume":"85","author":"Ermacora A","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(97)00160-4"},{"key":"e_1_2_5_56_2","first-page":"1151","article-title":"Liposome encapsulated daunorubicin doubles anthracycline toxicity in cell lines showing a non\u2010PGP related multidrug resistance","volume":"84","author":"Michieli M","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_5_57_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03437.x"},{"key":"e_1_2_5_58_2","doi-asserted-by":"publisher","DOI":"10.1159\/000207817"},{"key":"e_1_2_5_59_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/archinte.1968.00300100055013","article-title":"Kaposi's sarcoma associated with multiple myeloma. Report of a patient and review of the literature","volume":"122","author":"Mazzaferri EL","year":"1968","journal-title":"Arch Intern Med"},{"key":"e_1_2_5_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)91404-6"},{"key":"e_1_2_5_61_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5320.1851"},{"key":"e_1_2_5_62_2","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/blood.V90.11.4278","article-title":"Localization of Kaposi's sarcoma\u2010associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma","volume":"90","author":"Said JW","year":"1997","journal-title":"Blood"},{"key":"e_1_2_5_63_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.5-suppl_1-28"},{"key":"e_1_2_5_64_2","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2000.0188"},{"issue":"1","key":"e_1_2_5_65_2","first-page":"363a","article-title":"Bone marrow microvessel density is a prognostic factor for survival in multiple myeloma and a significant decrease in microvessel density occurs in patients who achieve a remission after chemotherapy","volume":"96","author":"Sezer O","year":"2000","journal-title":"Blood"},{"issue":"1","key":"e_1_2_5_66_2","first-page":"168a","article-title":"Thalidomide plus dexamethasone (THAL\/DEX) and thalidomide alone (THAL) as first line therapy for newly diagnosed myeloma (MM)","volume":"96","author":"Rajkumar SV","year":"2000","journal-title":"Blood"},{"issue":"1","key":"e_1_2_5_67_2","first-page":"167a","article-title":"Thalidomide with dexamethasone for resistant multiple myeloma","volume":"96","author":"Weber DM","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_68_2","first-page":"1111","article-title":"Low\u2010dose of thalidomide in the treatment of refractory myeloma","volume":"85","author":"Pini M","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_5_69_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01983.x"},{"key":"e_1_2_5_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009283431315"},{"key":"e_1_2_5_71_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/92.1.11"},{"key":"e_1_2_5_72_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428199909169624"},{"key":"e_1_2_5_73_2","first-page":"2115","article-title":"A Phase II study of high\u2010dose methylprednisolone in refractory or relapsed multiple myeloma","volume":"9","author":"Gertz MA","year":"1995","journal-title":"Leukemia"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10561","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:15:23Z","timestamp":1760289323000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10561"}},"subtitle":["A Phase II International Oncology Study Group study"],"short-title":[],"issued":{"date-parts":[[2002,5,14]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,5,15]]}},"alternative-id":["10.1002\/cncr.10561"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10561","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,14]]}}}